Systems and methods for bacterial load sensing devices are disclosed. An example contamination sensing device may comprise a body, a light emitter disposed on the body and configured to emit an excitation wavelength of light toward a surface, a sensor disposed on the body, configured to detect light, and directed toward the surface, and a filter adjuster configured to determine, based on the excitation wavelength of light, a filter configured to remove light outside of an emission wavelength range, wherein the emission wavelength range corresponds to wavelengths of light emitted by contamination upon exposure to the excitation wavelength of light, and adjustably move the filter in front of the sensor.

Methods, kits and reagents are provided for increasing the sensitivity of detecting the presence or absence of endospores by increasing the available protein for detection. The methods are fast and amendable to testing in a non-laboratory setting and use a protein detection reagent and solid microparticles.

Peptide and/or protein quantitation methods, kits, and compositions, particularly useful for mass spectrometry, are provided herein based on a bathocuproine-based composition complex such as bathocuproinedisulfonic acid disodium salt hydrate complex. The methods are one-step rapid absorbance methods using small sample volumes. They produce a robust signal with high signal to background ratio and accurately quantitate even complex peptide mixtures with low variability and high sensitivity.

The present invention is comprised in the field of glycobiology. In particular, it relates to a method for separating, in biological samples, the fraction bound to or associated with sulfated glycosaminoglycans (GAGs), and the applications thereof in biomedicine, such as for identifying the profile of glycoproteins or the profile of lipids bound to or associated with sulfated GAGs, detecting an alteration in the pattern of glycosylation by sulfated GAGs, identifying biomarkers for the diagnosis, for the prognosis, for monitoring the progression of a disease or of the effect of a therapy, or for identifying compounds suitable for the treatment of a disease. The invention also relates to methods for diagnosing mucopolysaccharidosis and for diagnosing and determining the prognosis of a kidney disease.

Methods of minimizing hook effect interference in an immunoassay are disclosed. Also disclosed are reagents, kits, and immunoassay devices that may be utilized in accordance with the method.

The present disclosure relates to a device and an in vitro method for quantitatively determining the presence or absence of one or more acute phase proteins in a biological sample from an individual. Said method comprises contacting a biological sample from the individual with a device to determine relative levels of acute phase proteins produced during bacterial infection and correlating the determined levels to infection. The device used is based on inverted methachromacy and the detection level of said method and device depends on the ratio of proteoaminoglycan to Toluidine blue in the solution. The device and method can detect a bacterial infection or monitor an antibiotic therapy.

This present disclosure provides methods and compositions that can be used to quantify cfDNA in biofluids using a hybridization approach.

This present disclosure provides methods and compositions that can be used to quantify cfDNA in biofluids using a hybridization approach.

The present specification discloses methods of characterizing a population of particles using a particle analyzer. Particles may be characterized by size, absolute number, whether the particle is non-proteinaceous or proteinaceous, whether a proteinaceous particle has or lacks a certain physical property, or any combination thereof.

Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia.